Xilio Therapeutics Inc
General ticker "XLO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $64.3M
Xilio Therapeutics Inc follows the US Stock Market performance with the rate: 18.6%.
Estimated limits based on current volatility of 11.4%: low 0.96$, high 1.21$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.43$, 1.54$]
- 2024-12-30 to 2025-12-30 estimated range: [0.48$, 1.54$]
Short-term XLO quotes
Long-term XLO plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $75.04MM | $89.15MM | $79.13MM |
| Operating Income | $-75.04MM | $-89.15MM | $-79.13MM |
| Non-Operating Income | $-0.76MM | $0.93MM | $2.73MM |
| Interest Expense | $0.60MM | $0.00MM | $0.00MM |
| R&D Expense | $51.19MM | $59.20MM | $52.14MM |
| Income(Loss) | $-75.80MM | $-88.22MM | $-76.40MM |
| Profit(Loss) | $-75.80MM | $-88.22MM | $-76.40MM |
| Stockholders Equity | $185.43MM | $105.65MM | $36.83MM |
| Assets | $218.06MM | $139.16MM | $60.93MM |
| Operating Cash Flow | $-80.75MM | $-75.72MM | $-68.62MM |
| Capital expenditure | $1.10MM | $1.87MM | $0.49MM |
| Investing Cash Flow | $-1.10MM | $-1.87MM | $-0.49MM |
| Financing Cash Flow | $260.67MM | $-0.07MM | $-6.55MM |
| Earnings Per Share* | $-2.72 | $-3.19 | $-2.78 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.